IPH5201 as monotherapy or in combination with durvalumab +/- oleclumab in participants with advanced solid tumors.

Trial Identifier:	D6770C00001
Sponsor:	MedImmune, LLC
NCTID::	NCT04261075
Start Date:	March 2020
Primary Completion Date:	June 2022
Study Completion Date:	June 2022
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	German (Switzerland) Translation
	Spanish (Spain) Translation
	Spanish (United States) Translation
	French (Switzerland) Translation
	Italian (Switzerland) Translation
	Portuguese (United States) Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CH	Lausanne, CH, 1011
ES	Barcelona, ES, 8035
ES	Madrid, ES, 28027
FR	BORDEAUX CEDEX, FR, 33076
FR	Villejuif, FR, 94805
US, NC	Huntersville, NC, US, 28078
US, RI	Providence, RI, US, 02906
US, TN	Nashville, TN, US, 37203

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company